Nattawat Klomjit (@basmeomeo) 's Twitter Profile
Nattawat Klomjit

@basmeomeo

Someone who love kidneys and physiology😷| He, him, his.

ID: 840452261058826240

calendar_today11-03-2017 06:40:08

354 Tweet

348 Followers

286 Following

Mayo Clinic Nephrology (@mayoclinicneph) 's Twitter Profile Photo

The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney biopsy in patients with monoclonal gammopathy Ladan Zand Nattawat Klomjit maria jose vargas Sanjeev Sethi fernando fervenza kidney-international.org/article/S0085-…

Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo

Just out. Updated myeloma mSMART guidelines on prevention and management of bispecific antibody associated Toxicities. Yi Lin Mayo Myeloma #ASCO25 Comprehensive and covers CRS, neurotoxicity, infection prevention and more. Link: msmart.org/mm-treatment-g…

Just out. Updated myeloma mSMART guidelines on prevention and management of bispecific antibody associated Toxicities. <a href="/YiLinMDPhD/">Yi Lin</a> <a href="/MayoMyeloma/">Mayo Myeloma</a> 
#ASCO25 

Comprehensive and covers CRS, neurotoxicity, infection prevention and more. 

Link: msmart.org/mm-treatment-g…
Rajiv Agarwal MD, MS (@agarwalrajivmd) 's Twitter Profile Photo

More than 50% reduction in uacr with combo and about 30% with each component that is empagliflozin and finerenone. Time to consider simultaneous initiation of combination therapy in ckd and t2d as in hfref and stage 2 hypertension.

Andrea Angioi, MD, FASN (@andreaangioi) 's Twitter Profile Photo

Stunning interim results from the VISIONARY Phase 3 trial in IgA nephropathy! Sibeprenlimab 400 mg led to a 51.2% placebo-adjusted reduction in 24h proteinuria (uPCR), with a -50.2% absolute reduction at 9 months! 🔵 Placebo barely moved the needle: +2.1%. 📉 Early and sustained

Stunning interim results from the VISIONARY Phase 3 trial in IgA nephropathy!
Sibeprenlimab 400 mg led to a 51.2% placebo-adjusted reduction in 24h proteinuria (uPCR), with a -50.2% absolute reduction at 9 months! 🔵
Placebo barely moved the needle: +2.1%.

📉 Early and sustained
Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo

The International Myeloma Working Group (IMWG) develops criteria for diagnosis, risk-strat, & response, provides current treatment guidelines, conducts collaborative research Bookmark our website: IMWG experts searchable by name and region IMWG.org International Myeloma Foundation

Johann Morelle (@johannmorelle) 's Twitter Profile Photo

#Complement Activation in Secondary Thrombotic Microangiopathies (#TMA) ✅ Final version available in #OpenAccess in NDT ➡️ academic.oup.com/ndt/advance-ar… 🙏 experts, colleagues and friends; the ERA - European Renal Association Immunonephrology Working Group; and Andreas Kronbichler for your leadership!

#Complement Activation in Secondary Thrombotic Microangiopathies (#TMA)

✅ Final version available in #OpenAccess in <a href="/NDTsocial/">NDT</a>

➡️ academic.oup.com/ndt/advance-ar…

🙏 experts, colleagues and friends; the <a href="/ERAkidney/">ERA - European Renal Association</a> Immunonephrology Working Group; and <a href="/AKronbichler/">Andreas Kronbichler</a> for your leadership!
Sanjeev Sethi (@sethirenalpath) 's Twitter Profile Photo

Sorry I accidentally deleted the original post while trying to answer some questions. I’m still a novice with X 😁 Take home message: small ~3% of PLA2R negative MN cases by routine IF are PLA2R positive by LMD/MS. kidney-international.org/article/S0085-…